Adjuvant sintilimab effective in high-risk HCC
Crossref DOI link: https://doi.org/10.1038/s41571-024-00865-3
Published Online: 2024-02-05
Published Print: 2024-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sidaway, Peter
Text and Data Mining valid from 2024-02-05
Version of Record valid from 2024-02-05
Article History
First Online: 5 February 2024